undamentalytics Newsletter
Sign in

Invivyd, Inc. (IVVD) stock

Add to watchlist

Add holding +

NASDAQ: IVVD Nasdaq Biotechnology Next results ~November 5, 2026

C Fundamentals grade

Invivyd, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.2

Price-to-sales vs peers

Base case. Range ~$0.2–$1.9. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Invivyd, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 5 selling1 purchase and 20 sales by directors and officers, last 12 monthsInsider trades
  • Funds71 adding, 71 cuttingOf 30 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Invivyd files

Where Invivyd stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $58m, up 26.3% on a year earlier, slower than the 52.3% growth a quarter earlier. Free-cash-flow margin rose to -187.9% from -245.1% a year earlier. Operating margin widened to -192.8% from -245.7%. The diluted share count is up 14.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $0.46 a share, against a share price of $0.60.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Invivyd, Inc.'s trailing-twelve-month revenue grew 26.3% year on year, with a free-cash-flow margin of -187.9%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 26.3% (-26.0pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 26.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 52.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Growth slowing. The growth rate is 26.0 points lower than a quarter earlier.
  • Loss-making. Operating margin is -192.8%: costs exceed revenue.
  • Burning cash. Free cash flow was -187.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 19.2% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 14.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 109% and a beta of 2.0 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.14 against an average estimate of -$0.14: beat by 0.0%
Revenue
$14m, up 21.2% on a year earlier
Share reaction
-1.5% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.15

Invivyd's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-1.2%
  • 1 month-29.2%
  • This year-76.4%
  • 1 year-66.9%
  • 5 years-98.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$58.4M
Operating margin
-192.8%
Net margin
-183.9%
EPS (TTM, diluted)
$-0.81

Growth

Revenue growth
+26.3%
Change in growth rate
−26.0 pts
Share count change
+14.0%

Cash

Free cash flow (TTM)
-$110M
FCF margin
-187.9%
Stock pay % of revenue
19.2%

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Results
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Invivyd, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Invivyd, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.48 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$0.5–$1.9 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.2 ~$0.2–$1.9 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Invivyd, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025
Share price$3.94$0.44$2.47
Market value$432m$53m$425m
+ Net debt (− = net cash)−$201m−$69m−$227m
Enterprise value$231m−$17m$199m
Multiples
Price / sales —2.1x8.0x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026. Analysts expect revenue of $15m and EPS of −$0.15 (range −$0.15 to −$0.15) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.57 −90% $60m +12%
Next −$0.55 +4% $87m +45%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +7.5% on 90 days ago. In the last 30 days, 0 analysts raised Invivyd, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Invivyd, Inc., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.53 Current fiscal year, 60 days ago: −$0.53 Current fiscal year, 30 days ago: −$0.57 Current fiscal year, 7 days ago: −$0.57 Current fiscal year, Now: −$0.57 −$0.57 Next fiscal year, 90 days ago: −$0.58 Next fiscal year, 60 days ago: −$0.58 Next fiscal year, 30 days ago: −$0.55 Next fiscal year, 7 days ago: −$0.55 Next fiscal year, Now: −$0.55 −$0.55

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.53−$0.58
60 days ago −$0.53−$0.58
30 days ago −$0.57−$0.55
7 days ago −$0.57−$0.55
Now −$0.57−$0.55

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.14 −$0.14 0.0%
Mar 2026 −$0.08 −$0.13 −62.5%
Sept 2025 −$0.10 −$0.06 +36.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Invivyd, Inc.'s latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202633
  2. Sep 202633
  3. Aug 202633

Counts of recommendations published by analysts covering Invivyd, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.9%
of tradable shares
Days to cover
5.01
at average volume
Short interest, 1 month
+21%
to October 15, 2026
Held by institutions
87%
of shares
Held by insiders
7.2%
of shares
Employees
122
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
IVVD−79%+163%−89%+458%−76%
Industry peers (median)−56%−18%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
IVVD42%42%33%67%18%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
IVVD−86%−58%−92%−78%−79%
S&P 500−25%−10%−8%−19%−9%

Worst fall since August 6, 2021: 99% from September 16, 2021 to January 31, 2025. Getting back needed a 15565% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.54 – $2.88
From 52-week high
−79.8%
vs 50-day average
−25.2%
vs 200-day average
−49.6%
Volatility (1 year)
109%
Beta vs S&P 500
1.97

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±27.8%
After a week
5 up, 7 down
typical move ±43.6%
After a month
5 up, 7 down
typical move ±46.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −1.5% +0.5% +29.9% +21.9%
May 14, 2026 −17.7% −0.4% −24.5% −40.9%
March 5, 2026 +5.3% −1.9% +5.3% −24.0%
January 8, 2026 +5.0% +0.7% +1.7% −38.3%
November 6, 2025 +4.3% −1.0% +16.4% +56.6%
August 14, 2025 −10.8% −0.2% −33.4% +61.4%
May 15, 2025 −7.1% +1.1% −9.0% −5.7%
March 20, 2025 +2.5% −0.3% −15.3% −22.1%
February 3, 2025 +249.2% 0.0% +338.5% +196.1%
November 14, 2024 −15.2% −1.9% −21.3% −49.3%
October 29, 2024 −12.5% −0.1% −11.2% −35.2%
August 14, 2024 −1.9% +2.0% −17.2% +8.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Invivyd, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Invivyd, Inc.
$0 $20M $40M $60M FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue (TTM), FY24 Q1: $0 Revenue (TTM), FY24 Q2: $2.3M Revenue (TTM), FY24 Q3: $11.6M Revenue (TTM), FY24 Q4: $25.4M Revenue (TTM), FY25 Q1: $36.7M Revenue (TTM), FY25 Q2: $46.2M Revenue (TTM), FY25 Q3: $50M Revenue (TTM), FY25 Q4: $53.4M Revenue (TTM), FY26 Q1: $55.9M Revenue (TTM), FY26 Q2: $58.4M $58.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $0
FY24 Q2 $2.3M
FY24 Q3 $11.6M
FY24 Q4 $25.4M
FY25 Q1 $36.7M
FY25 Q2 $46.2M
FY25 Q3 $50M
FY25 Q4 $53.4M
FY26 Q1 $55.9M
FY26 Q2 $58.4M
Revenue growth, TTM YoY Invivyd, Inc.
0% 500% 1000% 1500% 2000% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: 1941.1% Revenue growth, TTM YoY, FY25 Q3: 332.7% Revenue growth, TTM YoY, FY25 Q4: 110.5% Revenue growth, TTM YoY, FY26 Q1: 52.3% Revenue growth, TTM YoY, FY26 Q2: 26.3% 26.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 1941.1%
FY25 Q3 332.7%
FY25 Q4 110.5%
FY26 Q1 52.3%
FY26 Q2 26.3%
Operating margin (TTM) Invivyd, Inc.
-10000% -5000% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: -9503.0% Operating margin (TTM), FY24 Q3: -2027.0% Operating margin (TTM), FY24 Q4: -696.8% Operating margin (TTM), FY25 Q1: -402.6% Operating margin (TTM), FY25 Q2: -245.7% Operating margin (TTM), FY25 Q3: -124.4% Operating margin (TTM), FY25 Q4: -104.0% Operating margin (TTM), FY26 Q1: -146.4% Operating margin (TTM), FY26 Q2: -192.8% -192.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -9503.0%
FY24 Q3 -2027.0%
FY24 Q4 -696.8%
FY25 Q1 -402.6%
FY25 Q2 -245.7%
FY25 Q3 -124.4%
FY25 Q4 -104.0%
FY26 Q1 -146.4%
FY26 Q2 -192.8%
FCF margin (TTM) Invivyd, Inc.
-10000% -5000% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q2: -8239.6% FCF margin (TTM), FY24 Q3: -1662.6% FCF margin (TTM), FY24 Q4: -672.2% FCF margin (TTM), FY25 Q1: -385.8% FCF margin (TTM), FY25 Q2: -245.1% FCF margin (TTM), FY25 Q3: -160.8% FCF margin (TTM), FY25 Q4: -109.1% FCF margin (TTM), FY26 Q1: -142.2% FCF margin (TTM), FY26 Q2: -187.9% -187.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -8239.6%
FY24 Q3 -1662.6%
FY24 Q4 -672.2%
FY25 Q1 -385.8%
FY25 Q2 -245.1%
FY25 Q3 -160.8%
FY25 Q4 -109.1%
FY26 Q1 -142.2%
FY26 Q2 -187.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 25 53 58
EBITDA −212 — — —
Operating income −213 −177 −56 −113
Net income −199 −170 −52 −107
Diluted EPS −$1.81 −$1.43 −$0.30 —
Growth (year on year)
Revenue — — +110.5% +26.3%
Margins
Operating margin — −696.8% −104.0% −192.8%
Net margin — −669.4% −98.2% −183.9%
Free-cash-flow margin — −672.2% −109.1% −187.9%
Cash flow
Cash from operations −173 −170 −58 −108
Capital spending 1 0 0 1
Free cash flow −174 −171 −58 −110
Stock-based pay 19 20 12 11
Free cash flow after stock pay −192 −190 −70 −121
Balance sheet
Cash 201 69 227 160
Total debt 0 0 0 0
Net debt (negative = net cash) −201 −69 −227 −160
Diluted shares 110m 119m 172m —
Returned to shareholders
Buybacks 0 0 — —
Total returned 0 0 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $219m
Short-term assets $182mLonger-term assets $37m
What it owes, and who funded it · $219m
Short-term liabilities $31mLonger-term liabilities $7mShareholders' equity $181m
  • Short-term assets cover short-term liabilities $182m of assets due within a year against $31m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $182m short-term assets against $7m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Invivyd, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+14.0%
year over year
R&D spending
134.0%
of revenue
Sales & admin spending
151.1%
of revenue
Days sales outstanding
70 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated IVVD FENC NTLA NKTR TNGX SIGA Median
Revenue, last 12 months $58m $59m $60m $55m $54m $54m $56m
Revenue growth, last 12 months 26.3% 77.8% 12.6% −27.2% 121.5% −70.1% 12.6%
Revenue growth, 3-year average — 566.5% 3.9% −14.6% 16.9% −18.1% 13.7%
Revenue growth, latest quarter 21.2% 85.2% −46.2% −9.3% −100.0% −49.5% 10.2%
Gross margin — 94.1% 100.0% 100.0% — 54.4% 82.9%
Operating margin −192.8% −1.9% −711.7% −257.8% −253.4% −20.8% −189.4%
Operating margin, 3-year average <−999% −6.3% −940.1% −189.3% −404.1% 31.6% −363.5%
Net margin −183.9% −5.5% −672.2% −287.8% −229.9% −5.2% −169.8%
Cash from operations / revenue −185.8% −3.4% −582.5% −428.3% −267.4% −37.6% −168.0%
Free-cash-flow margin −187.9% −3.4% −586.0% −428.7% −268.1% −38.2% −162.4%
Free-cash-flow margin, 3-year average <−999% 2.9% −738.8% −288.4% −388.7% 23.6% −310.0%
Stock pay / revenue 19.2% 12.7% 114.1% 22.0% 74.9% 6.5% 20.0%
Change in share count 14.0% 23.6% 16.6% 6.2% 21.8% 0.1% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 26.3% 12.6% 72 of 172
Change in growth rate Growth -26.0pp -0.1pp 131 of 172
Operating margin Profitability -192.8% -189.4% 89 of 175
Net margin Profitability -183.9% -157.3% 93 of 180
Free-cash-flow margin Cash generation -187.9% -145.4% 98 of 176
Stock pay as % of revenue Cash generation 19.2% 19.2% 90 of 179
Change in share count Balance sheet 14.0% 7.9% 101 of 156
Days sales outstanding Balance sheet 70 days 75 days 50 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$204M
Institutions reporting
125
Shares held vs prior quarter
▲ 2.0%
Positions opened / closed
33 / 45

Top buyers and sellers, Q2 2026: 71 institutions bought and 71 sold ; the biggest buyer was Blackrock, Inc (+11.9M shares) and the biggest seller Eventide Asset Management, LLC (−9.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jupiter Topco LLC $30M 34.2M 14.8% —
Bvf Inc $24.6M 28.2M 12.1% ▲ 44.3%
Maverick Capital Ltd $16.6M 19.0M 8.1% 0.0%
Perceptive Advisors LLC $16.1M 18.5M 7.9% ▼ 11.4%
Blackrock, Inc. $14.1M 16.1M 6.9% ▲ 276.8%
Vanguard Capital Management LLC $9.2M 10.5M 4.5% ▲ 4.2%
M28 Capital Management LP $8.1M 9.2M 4.0% 0.0%
Saturn V Capital Management LP $7.3M 8.4M 3.6% ▼ 23.4%
Soleus Capital Management, L.P. $6.7M 7.7M 3.3% 0.0%
Point72 Asset Management, L.P. $6.6M 7.5M 3.2% ▲ 17068.0%
Morgan Stanley $5M 5.7M 2.5% ▲ 69.1%
Geode Capital Management, LLC $4.7M 5.4M 2.3% ▲ 119.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Invivyd, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $125,000 1 trade by 1 insider, last 12 months Insider sales History → $531,074 20 trades by 5 insiders · 100% under pre-set plans
Net ▼ $406,074 net selling
Insider Date Trade Shares Price Value
Allen Robert D. Iii Chief Scientific Officer August 18, 2026 Sell pre-set plan 17,043 $0.84 $14,316
Andersen Jill Chief Legal Officer, Secretary August 18, 2026 Sell pre-set plan 30,706 $0.84 $25,793
Duke William E. Chief Financial Officer August 18, 2026 Sell pre-set plan 18,425 $0.84 $15,477
Green Julie Chief Human Resources Officer August 18, 2026 Sell pre-set plan 18,425 $0.84 $15,477
Lee Timothy Edward Chief Commercial Officer August 18, 2026 Sell pre-set plan 18,425 $0.84 $15,477
Allen Robert D. Iii Chief Scientific Officer August 17, 2026 Sell pre-set plan 20,679 $0.72 $14,889
Andersen Jill Chief Legal Officer, Secretary August 17, 2026 Sell pre-set plan 37,256 $0.72 $26,824
Duke William E. Chief Financial Officer August 17, 2026 Sell pre-set plan 22,355 $0.72 $16,096
Green Julie Chief Human Resources Officer August 17, 2026 Sell pre-set plan 22,355 $0.72 $16,096
Lee Timothy Edward Chief Commercial Officer August 17, 2026 Sell pre-set plan 22,355 $0.72 $16,096
Andersen Jill Chief Legal Officer, Secretary February 18, 2026 Sell pre-set plan 34,939 $1.58 $55,204
Lee Timothy Edward Chief Commercial Officer February 18, 2026 Sell pre-set plan 20,964 $1.58 $33,123

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 13, 2026
  • May 14, 2026
  • March 5, 2026
  • January 8, 2026
  • November 6, 2025
  • August 14, 2025

Recent SEC filings

Data status

When each part of this page on Invivyd, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Invivyd, Inc. in brief

What does Invivyd, Inc. do?
Invivyd, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Invivyd, Inc.'s stock ticker?
Invivyd, Inc. trades under the ticker IVVD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Invivyd, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Invivyd, Inc. reported revenue of $58.4M, 26.3% higher than a year earlier, according to its SEC filings.
What is Invivyd, Inc.'s free cash flow?
Invivyd, Inc.'s free-cash-flow margin is -187.9% of revenue over the trailing twelve months, ranking 98 of the 176 biotechnology companies we cover.
Who are Invivyd, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, Bvf Inc and Maverick Capital Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Invivyd, Inc.'s market cap?
On December 31, 2025, Invivyd, Inc.'s market capitalisation was about $425M and net debt of -$227M. Market figures come from third-party market data and may be delayed.
Who are Invivyd, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Invivyd, Inc. are Fennec Pharmaceuticals Inc., Intellia Therapeutics, Inc., Nektar Therapeutics, Tango Therapeutics, Inc. and Siga Technologies Inc. The side-by-side comparison below sets their revenue, margins and growth against Invivyd, Inc.'s.
Are insiders buying or selling Invivyd, Inc. stock?
Over the last 12 months, Invivyd, Inc.'s directors and officers reported 1 open-market purchases and 20 sales on Form 4. The insider trading page charts every trade.
When is Invivyd, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Invivyd, Inc. announces its own schedule.